Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552775 | 0.89 | HRH3 (0.61) | HRH3CYP2A13SMN1; SMN2POLBSIGMAR1 | |
| SCHEMBL5618352 | 0.86 | SMN1; SMN2 (0.71) | HRH3CYP2A13SMN1; SMN2POLBSIGMAR1 | |
| SCHEMBL3710220 | 0.86 | HRH3 (0.51) | HRH3CYP2A13SMN1; SMN2SIGMAR1DRD4 | |
| SCHEMBL6306548 | 0.83 | ALDH1A1 (0.72) | HRH3SMN1; SMN2POLBSIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16825107 | 0.82 | ALDH1A1 (0.70) | HRH3SMN1; SMN2POLBSIGMAR1ALDH1A1 | |
| SCHEMBL26117280 | 0.82 | POLB (0.51) | HRH3SMN1; SMN2POLBSIGMAR1DRD4 | |
| SCHEMBL17724081 | 0.81 | HRH3 (0.56) | HRH3CYP2A13SMN1; SMN2MEN1NPC1 | |
| SCHEMBL23235186 | 0.81 | HRH3 (0.54) | HRH3CYP2A13SMN1; SMN2DRD4NPC1 | |
| SCHEMBL538318 | 0.81 | HTT (0.58) | HRH3CYP2A13SMN1; SMN2NPC1TP53 | |
| SCHEMBL8257960 | 0.81 | HRH3 (0.54) | HRH3CYP2A13SMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459252-A | Imidazole-substituted pyrimidines for the treatment of glycogen synthase kinase 3 related diseases such as alzheimer's disease | ASTRAZENECA AB | 2012-05-16 | — | — | CN | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| EP-2419425-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120237-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120237-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | GSK3A, GSK3B, PYGB | HRH3 817/4885CYP2A13 2322/4885SMN1; SMN2 1134/4885 |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | GSK3B, GSK3A, STK3 | HRH3 210/4885CYP2A13 2087/4885SMN1; SMN2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.